WEREWOLF THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.2 USD | -0.64% |
|
-3.60% | +59.59% |
| Sales 2024 * | 5.83M 467M | Sales 2025 * | 12.38M 991M | Capitalization | 270M 21.66B |
|---|---|---|---|---|---|
| Net income 2024 * | -59M -4.72B | Net income 2025 * | -62M -4.96B | EV / Sales 2024 * | 46.4 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 21.9 x |
| P/E ratio 2024 * |
-4.74
x | P/E ratio 2025 * |
-5.02
x | Employees | 47 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.72% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.64% | ||
| 1 week | -3.60% | ||
| Current month | -1.28% | ||
| 1 month | -3.45% | ||
| 3 months | +29.41% | ||
| 6 months | +170.18% | ||
| Current year | +59.59% |
1 week
6.00
6.89
1 month
4.506.89
Current year
3.848.19
1 year
1.578.19
3 years
1.3921.67
5 years
1.3923.99
10 years
1.3923.99
| Managers | Title | Age | Since |
|---|---|---|---|
Dan Hicklin
FOU | Founder | 60 | 18/10/17 |
Luke Evnin
FOU | Founder | 60 | 18/10/17 |
Timothy Trost
DFI | Director of Finance/CFO | 66 | 07/02/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Luke Evnin
FOU | Founder | 60 | 18/10/17 |
Dan Hicklin
FOU | Founder | 60 | 18/10/17 |
Michael Sherman
BRD | Director/Board Member | 58 | 26/05/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 6.16 | -1.28% | 92 606 |
| 30/04/24 | 6.24 | -6.31% | 143,426 |
| 29/04/24 | 6.66 | -1.33% | 125,968 |
| 26/04/24 | 6.75 | +8.70% | 82,150 |
| 25/04/24 | 6.21 | -2.82% | 78,714 |
Delayed Quote Nasdaq, May 01, 2024 at 06:39 pm
More quotes
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the bodyâs immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.24
USD
Average target price
12.5
USD
Spread / Average Target
+100.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +59.59% | 270M | |
| +0.19% | 42.19B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +5.63% | 24.63B | |
| -23.20% | 18.2B | |
| +27.50% | 12.01B | |
| -2.93% | 11.76B | |
| +15.50% | 10.4B | |
| -4.78% | 9.94B |
- Stock Market
- Equities
- HOWL Stock
